Patrick Ryan
Patrick Ryan
Janssen Research and Development
Geverifieerd e-mailadres voor cornell.edu
Titel
Geciteerd door
Geciteerd door
Jaar
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
6302015
Novel data‐mining methodologies for adverse drug event discovery and analysis
R Harpaz, W DuMouchel, NH Shah, D Madigan, P Ryan, C Friedman
Clinical Pharmacology & Therapeutics 91 (6), 1010-1021, 2012
3512012
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership
PE Stang, PB Ryan, JA Racoosin, JM Overhage, AG Hartzema, C Reich, ...
Annals of internal medicine 153 (9), 600-606, 2010
3492010
Validation of a common data model for active safety surveillance research
JM Overhage, PB Ryan, CG Reich, AG Hartzema, PE Stang
Journal of the American Medical Informatics Association 19 (1), 54-60, 2012
3132012
Characterizing treatment pathways at scale using the OHDSI network
G Hripcsak, PB Ryan, JD Duke, NH Shah, RW Park, V Huser, MA Suchard, ...
Proceedings of the National Academy of Sciences 113 (27), 7329-7336, 2016
2362016
Performance of pharmacovigilance signal‐detection algorithms for the FDA adverse event reporting system
R Harpaz, W DuMouchel, P LePendu, A Bauer‐Mehren, P Ryan, ...
Clinical Pharmacology & Therapeutics 93 (6), 539-546, 2013
2292013
A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data
MG Kahn, TJ Callahan, J Barnard, AE Bauck, J Brown, BN Davidson, ...
Egems 4 (1), 2016
1972016
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership
PB Ryan, D Madigan, PE Stang, J Marc Overhage, JA Racoosin, ...
Statistics in medicine 31 (30), 4401-4415, 2012
1712012
Evaluating the impact of database heterogeneity on observational study results
D Madigan, PB Ryan, M Schuemie, PE Stang, JM Overhage, ...
American journal of epidemiology 178 (4), 645-651, 2013
1582013
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled …
JCE Lane, J Weaver, K Kostka, T Duarte-Salles, MTF Abrahao, H Alghoul, ...
MedRXiv, 2020
1492020
Interpreting observational studies: why empirical calibration is needed to correct p‐values
MJ Schuemie, PB Ryan, W DuMouchel, MA Suchard, D Madigan
Statistics in medicine 33 (2), 209-218, 2014
1492014
Search for gravitational waves from binary black hole inspiral, merger, and ringdown
J Abadie, BP Abbott, R Abbott, M Abernathy, T Accadia, F Acernese, ...
Physical Review D 83 (12), 122005, 2011
1472011
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 …
PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ...
Diabetes, Obesity and Metabolism 20 (11), 2585-2597, 2018
1402018
Feasibility and utility of applications of the common data model to multiple, disparate observational health databases
EA Voss, R Makadia, A Matcho, Q Ma, C Knoll, M Schuemie, FJ DeFalco, ...
Journal of the American Medical Informatics Association 22 (3), 553-564, 2015
1352015
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
MA Suchard, MJ Schuemie, HM Krumholz, SC You, RJ Chen, N Pratt, ...
The Lancet 394 (10211), 1816-1826, 2019
1252019
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
E Abaleke, M Abbas, S Abbasi, A Abbott, A Abdelaziz, S Abdelbadiee, ...
The Lancet 397 (10274), 605-612, 2021
1142021
Defining a reference set to support methodological research in drug safety
PB Ryan, MJ Schuemie, E Welebob, J Duke, S Valentine, AG Hartzema
Drug safety 36 (1), 33-47, 2013
1112013
Feasibility of using real-world data to replicate clinical trial evidence
VL Bartlett, SS Dhruva, ND Shah, P Ryan, JS Ross
JAMA network open 2 (10), e1912869-e1912869, 2019
1072019
Disproportionality methods for pharmacovigilance in longitudinal observational databases
I Zorych, D Madigan, P Ryan, A Bate
Statistical methods in medical research 22 (1), 39-56, 2013
1052013
A curated and standardized adverse drug event resource to accelerate drug safety research
JM Banda, L Evans, RS Vanguri, NP Tatonetti, PB Ryan, NH Shah
Scientific data 3 (1), 1-11, 2016
1002016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20